Melanoma Cancer Contract Phase 1 was Aethlon Medical’s largest revenue line in fiscal 2019, bringing in $149.63K of $229.63K (65%).
| Deferred Revenue Arrangement Type | FY 2018 | FY 2019 |
|---|---|---|
| Melanoma Cancer Contract Phase 1 | — | $149.63K |
| Melanoma Cancer Contract | $149.63K | — |
| Breast Cancer Grant | — | $80.00K |
| Total | $149.63K | $229.63K |
Aethlon Medical brought in $229.63K from its two revenue lines in fiscal 2019, the year ended March 31, 2019. Aethlon Medical regrouped these revenue lines after fiscal 2018, so the total does not compare directly with that year's $149.63K. Melanoma Cancer Contract Phase 1 was the largest at $149.63K (65.2%), ahead of Breast Cancer Grant at $80.00K (34.8%).
Aethlon Medical began breaking out Melanoma Cancer Contract Phase 1 in fiscal 2019 and Breast Cancer Grant in fiscal 2019. Aethlon Medical stopped reporting Melanoma Cancer Contract as a separate revenue line after fiscal 2018, when it brought in $149.63K.
Aethlon Medical (AEMD) reports its revenue by deferred revenue arrangement type. In fiscal 2019, Melanoma Cancer Contract Phase 1 was its largest revenue line, bringing in $149.63K (65.2% of the total), followed by Breast Cancer Grant at $80.00K (34.8%).
Melanoma Cancer Contract Phase 1 was Aethlon Medical's largest revenue line in fiscal 2019, bringing in $149.63K, or 65.2% of the $229.63K total across its two revenue lines.
Every figure comes from Aethlon Medical's annual financial filings, as reported. Each line keeps the name Aethlon Medical gives it, and years follow its fiscal calendar.
Aethlon Medical's revenue by deferred revenue arrangement type goes back to fiscal 2018, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.